Effects of varenicline on abstinence and smoking reward following a programmed lapse

Research output: Contribution to journalArticle

Abstract

Introduction: Varenicline (Chantix®) is an efficacious firstline medication for smoking cessation. Studies suggest that one mechanism by which varenicline facilitates sustained smoking abstinenceis by reducing the likelihood of relapse to smoking when a lapse, or slip, occurs during a quit attempt. The present study extends this line of research by conducting a prospective laboratory study to examine the relapse prevention effects of varenicline following a programmed lapse. Methods: Dailysmokers (N = 47) completed a 5-week outpatient study in which they were randomized to receive varenicline or placebo. The first week was a medication induction period that was immediately followed by a 4-week quit attempt. A programmed lapse (2 cigarettes smoked in the laboratory) occurred on the secondday of the quit attempt. Results: Participants receiving varenicline were slower to relapse and hadgreater total abstinence rates following lapse exposure. Participants in the varenicline group ratedlapse cigarettes lower on measures of reward and intoxication and showed increased behavioral economic demand elasticity for cigarettes (reduced cigarette purchasing at higher prices) compared with those receiving placebo. Conclusions: These results demonstrate a relapse prevention effect of varenicline following smoking lapse exposure and suggest that an attenuation of reward from smoking and the blunting of subjective effects of smoking may underlie and/or contribute to this effect.

Original languageEnglish (US)
Pages (from-to)139-148
Number of pages10
JournalNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Volume15
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Reward
Smoking
Tobacco Products
Secondary Prevention
Behavioral Economics
Placebos
Recurrence
Varenicline
Elasticity
Smoking Cessation
Outpatients
Prospective Studies
Research

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{ad3e6d4b6e034c179c2f9e4b9124e280,
title = "Effects of varenicline on abstinence and smoking reward following a programmed lapse",
abstract = "Introduction: Varenicline (Chantix{\circledR}) is an efficacious firstline medication for smoking cessation. Studies suggest that one mechanism by which varenicline facilitates sustained smoking abstinenceis by reducing the likelihood of relapse to smoking when a lapse, or slip, occurs during a quit attempt. The present study extends this line of research by conducting a prospective laboratory study to examine the relapse prevention effects of varenicline following a programmed lapse. Methods: Dailysmokers (N = 47) completed a 5-week outpatient study in which they were randomized to receive varenicline or placebo. The first week was a medication induction period that was immediately followed by a 4-week quit attempt. A programmed lapse (2 cigarettes smoked in the laboratory) occurred on the secondday of the quit attempt. Results: Participants receiving varenicline were slower to relapse and hadgreater total abstinence rates following lapse exposure. Participants in the varenicline group ratedlapse cigarettes lower on measures of reward and intoxication and showed increased behavioral economic demand elasticity for cigarettes (reduced cigarette purchasing at higher prices) compared with those receiving placebo. Conclusions: These results demonstrate a relapse prevention effect of varenicline following smoking lapse exposure and suggest that an attenuation of reward from smoking and the blunting of subjective effects of smoking may underlie and/or contribute to this effect.",
author = "McClure, {Erin A.} and Vandrey, {Ryan G} and Johnson, {Matthew W} and Stitzer, {Maxine L}",
year = "2013",
month = "1",
doi = "10.1093/ntr/nts101",
language = "English (US)",
volume = "15",
pages = "139--148",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Effects of varenicline on abstinence and smoking reward following a programmed lapse

AU - McClure, Erin A.

AU - Vandrey, Ryan G

AU - Johnson, Matthew W

AU - Stitzer, Maxine L

PY - 2013/1

Y1 - 2013/1

N2 - Introduction: Varenicline (Chantix®) is an efficacious firstline medication for smoking cessation. Studies suggest that one mechanism by which varenicline facilitates sustained smoking abstinenceis by reducing the likelihood of relapse to smoking when a lapse, or slip, occurs during a quit attempt. The present study extends this line of research by conducting a prospective laboratory study to examine the relapse prevention effects of varenicline following a programmed lapse. Methods: Dailysmokers (N = 47) completed a 5-week outpatient study in which they were randomized to receive varenicline or placebo. The first week was a medication induction period that was immediately followed by a 4-week quit attempt. A programmed lapse (2 cigarettes smoked in the laboratory) occurred on the secondday of the quit attempt. Results: Participants receiving varenicline were slower to relapse and hadgreater total abstinence rates following lapse exposure. Participants in the varenicline group ratedlapse cigarettes lower on measures of reward and intoxication and showed increased behavioral economic demand elasticity for cigarettes (reduced cigarette purchasing at higher prices) compared with those receiving placebo. Conclusions: These results demonstrate a relapse prevention effect of varenicline following smoking lapse exposure and suggest that an attenuation of reward from smoking and the blunting of subjective effects of smoking may underlie and/or contribute to this effect.

AB - Introduction: Varenicline (Chantix®) is an efficacious firstline medication for smoking cessation. Studies suggest that one mechanism by which varenicline facilitates sustained smoking abstinenceis by reducing the likelihood of relapse to smoking when a lapse, or slip, occurs during a quit attempt. The present study extends this line of research by conducting a prospective laboratory study to examine the relapse prevention effects of varenicline following a programmed lapse. Methods: Dailysmokers (N = 47) completed a 5-week outpatient study in which they were randomized to receive varenicline or placebo. The first week was a medication induction period that was immediately followed by a 4-week quit attempt. A programmed lapse (2 cigarettes smoked in the laboratory) occurred on the secondday of the quit attempt. Results: Participants receiving varenicline were slower to relapse and hadgreater total abstinence rates following lapse exposure. Participants in the varenicline group ratedlapse cigarettes lower on measures of reward and intoxication and showed increased behavioral economic demand elasticity for cigarettes (reduced cigarette purchasing at higher prices) compared with those receiving placebo. Conclusions: These results demonstrate a relapse prevention effect of varenicline following smoking lapse exposure and suggest that an attenuation of reward from smoking and the blunting of subjective effects of smoking may underlie and/or contribute to this effect.

UR - http://www.scopus.com/inward/record.url?scp=84871589226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871589226&partnerID=8YFLogxK

U2 - 10.1093/ntr/nts101

DO - 10.1093/ntr/nts101

M3 - Article

C2 - 22573730

AN - SCOPUS:84871589226

VL - 15

SP - 139

EP - 148

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 1

ER -